Description: H.Amdt. 224 — 116th Congress (2019-2020)All Information (Except Text)

As of 06/18/2019 the description for this amendment has not been received.


An amendment numbered 5 printed in House Report 116-61 to Commission a study by the National Academy of Medicine into the amount of federal funding and research used in the development of drugs by pharmaceutical companies, and to put measures in place to curb excessive drug costs.

House Amendment Code:


House Tally Clerks use this code to manage amendment information.